A Single-Arm, Multicenter, Exploratory Clinical Study of Transarterial Chemoembolization (TACE) Combined With Iparomlimab and Tuvonralimab Injection and Bevacizumab Injection for the Treatment of Unresectable, Non-Metastatic Hepatocellular Carcinoma (HCC)

NCT07128251 · clinicaltrials.gov ↗

PHASE2

Phase

NOT_YET_RECRUITING

Status

47

Enrollment

OTHER_GOV

Sponsor class

Conditions

Hepatocellular Carcinoma (HCC)
Immunotherapy
PD-1
CTLA-4
TACE

Interventions

PROCEDURE: TACE treatment
DRUG: Iparomlimab and Tuvonralimab Injection (QL1706)
DRUG: Bevacizumab

Sponsor

Anhui Provincial Hospital

Collaborators

[object Object]
[object Object]
[object Object]
[object Object]
[object Object]
[object Object]